The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies
Open accessAbstract
Background Whether triglyceride-mediated pathways are causally relevant to coronary heart disease is uncertain. We studied a genetic variant that regulates triglyceride concentration to help judge likelihood of causality.Methods We assessed the -1131T>C (rs662799) promoter polymorphism of the apolipoprotein A5 (APOA5) gene in relation to triglyceride concentration, several other risk factors, and risk of coronary heart disease. We compared disease risk for genetically-raised triglyceride concentration (20,842 patients with coronary heart disease, 35,206 controls) with that recorded for equivalent differences in circulating triglyceride concentration in prospective studies (302 430 participants with no history of cardiovascular disease; 12,785 incident cases of coronary heart disease during 2.79 million person-years at risk). We analysed -1131T>C in 1795 people without a history of cardiovascular disease who had information about lipoprotein concentration and diameter obtained by nuclear magnetic resonance spectroscopy.Findings The minor allele frequency of -1131T>C was 8% (95% CI 7-9). -1131T>C was not significantly associated with several non-lipid risk factors or LDL cholesterol, and it was modestly associated with lower HDL cholesterol (mean difference per C allele 3.5% [95% CI 2.6-4.6]; 0.053 mmol/L [0.039-0.068]), lower apolipoprotein AI (1.3% [0.3-2.3]; 0.023 g/L [0.005-0.041]), and higher apolipoprotein B (3.2% [1.3-5.1]; 0.027 g/L [0.011-0.043]). By contrast, for every C allele inherited, mean triglyceride concentration was 16.0% (95% CI 12.9-18.7), or 0.25 mmol/L (0.20-0.29), higher (p=4.4x10(-24)). The odds ratio for coronary heart disease was 1.18 (95% CI 1.11-1.26; p=2.6x10(-7)) per C allele, which was concordant with the hazard ratio of 1.10 (95% CI 1.08-1.12) per 16% higher triglyceride concentration recorded in prospective studies. -1131T>C was significantly associated with higher VLDL particle concentration (mean difference per C allele 12.2 nmol/L [95% CI 7.7-16.7]; p=9.3x10(-8)) and smaller HDL particle size (0.14 nm [0.08-0.20]; p=7.0x10(-5)), factors that could mediate the effects of triglyceride.Interpretation These data are consistent with a causal association between triglyceride-mediated pathways and coronary heart disease.Funding British Heart Foundation, UK Medical Research Council, Novartis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Non-HDL-C also includes the atherogenic TG-rich lipoproteins (VLDL, IDL and remnants), which is essential considering the recent information from genome-wide association studies (GWASs) and Mendelian randomization 76,86 - 89 supporting TGs and remnant particles as causative factors in atherogenesis.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Although the CVD risk is increased if fasting TGs are . 1.7 mmol/ L (150 mg/dL), 87 the use of drugs to lower TGs may only be considered in high-risk subjects when TGs are . 2.3 mmol/L (200 mg/dL) and cannot be lowered by lifestyle measures.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of the current study extend those findings by suggesting that triglyceride-rich remnant particles have approximately the same effect on the risk of cardiovascular disease as LDL particles.”
From Association of Triglyceride-Lowering LPL Variants and LDL-C–Lowering LDLR Variants With Risk of Coronary Heart Disease (2019) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The association between triglycerides and cardiovascular (CV) risk is well established from epidemiological studies,1-5 genome-wide analyses,6-8 and Mendelian randomization studies.9,10”
In the citing paper
“Therefore, the clinical benefit of therapies that lower LDL-C by reducing LDL particle mass will be proportional to the absolute reduction in LDLC, because-on average-the reduction in LDL-C and LDL particles will be concordant [34,50,54,55].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“The beneficial effect of ezetimibe is also supported by genetic studies of mutations in NPC1L1; naturally occurring mutations that inactivate the protein were found to be associated with reduced plasma LDL-C and reduced risk for CAD [55,269,270].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [55]
In the citing paper
“Although the role of TG as a risk factor for CVD has been strongly debated, recent data strongly favour the role of TG-rich lipoproteins as a risk factor for CVD.121”
From ESC/EAS Guidelines for the management of dyslipidaemias (2011) · cites this paper as [121]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization. 87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“Although the role of TGs as a risk factor for CVD has been strongly debated, recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“The causative role of HDL-C for protection against CVD has been questioned in several studies utilizing Mendelian randomization.87,89,91,92”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
In the citing paper
“recent data favour the role of TG-rich lipoproteins as a risk factor for CVD.87”
From 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias (2016) · cites this paper as [87]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Measuring inconsistency in meta-analyses
Higgins, J. P. T., Thompson, S. G., Deeks, J. J., & Altman, D. G. (2003) · BMJ · doi:10.1136/bmj.327.7414.557 · Cited by 63,139
Davey Smith, G., & Ebrahim, S. (2003) · International Journal of Epidemiology · doi:10.1093/ije/dyg070 · Cited by 5,882
Major lipids, apolipoproteins, and risk of vascular disease
The Emerging Risk Factors Collaboration* (2009) · JAMA · doi:10.1001/jama.2009.1619 · Cited by 2,731
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A.-M., & Pająk, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,260
Nordestgaard, B. G., Benn, M., Schnohr, P., & Tybjærg-Hansen, A. (2007) · JAMA · doi:10.1001/jama.298.3.299 · Cited by 2,058
Sarwar, N., Danesh, J., Eiriksdottir, G., Sigurdsson, G., Wareham, N., Bingham, S., Boekholdt, S. M., Khaw, K.-T., & Gudnason, V. (2007) · Circulation · doi:10.1161/circulationaha.106.637793 · Cited by 1,408
Kathiresan, S., Melander, O., Guiducci, C., Surti, A., Burtt, N. P., Rieder, M. J., Cooper, G. M., Roos, C., Voight, B. F., Havulinna, A. S., et al. (2008) · Nature Genetics · doi:10.1038/ng.75 · Cited by 1,386
Thompson, A. (2008) · JAMA · doi:10.1001/jama.299.23.2777 · Cited by 498
Sattar, N. A., McConnachie, A., Shaper, A. G., Blauw, G. J., Buckley, B. M., de Craen, A. J. M., Ford, I., Forouhi, N. G., Freeman, D. J., Jukema, J. W., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60602-9 · Cited by 492
Keating, B. J., Tischfield, S. E., Murray, S. S., Bhangale, T., Price, T. S., Glessner, J., Galver, L., Barrett, J. C., Grant, S. F. A., Farlow, D., et al. (2008) · PLoS ONE · doi:10.1371/journal.pone.0003583 · Cited by 373
Cited by
Sorted by citations
Items 101–200 of 716
Elevated Remnant Cholesterol Reclassifies Risk of Ischemic Heart Disease and Myocardial Infarction
Doi, T., Langsted, A., & Nordestgaard, B. G. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.03.384 · Cited by 129
Yetley, E. A., MacFarlane, A. J., Greene-Finestone, L. S., Garza, C., Ard, J. D., Atkinson, S. A., Bier, D. M., Carriquiry, A. L., Harlan, W. R., Hattis, D. B., et al. (2016) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.116.139097 · Cited by 130
Impact of Aging on the Strength of Cardiovascular Risk Factors: A Longitudinal Study Over 40 Years
Lind, L., Sundström, J., Ärnlöv, J., & Lampa, E. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.117.007061 · Cited by 124
Shared Risk Factors between Dementia and Atherosclerotic Cardiovascular Disease
Nordestgaard, L. T., Christoffersen, M., & Frikke‐Schmidt, R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23179777 · Cited by 128
Genomic study in Mexicans identifies a new locus for triglycerides and refines European lipid loci
Weissglas‐Volkov, D., Aguilar-Salinas, C. A., Nikkola, E., Deere, K. A., Cruz‐Bautista, I., Arellano‐Campos, O., Muñóz-Hernández, L. L., Gómez-Munguía, L., Ordóñez-Sánchez, M. L., Reddy, P. M. V. L., et al. (2013) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2012-101461 · Cited by 121
Toth, P. P., Granowitz, C., Hull, M., Liassou, D., Anderson, A., & Philip, S. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.008740 · Cited by 117
Demystifying the management of hypertriglyceridaemia
Watts, G. F., Ooi, E. M. M., & Chan, D. C. (2013) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2013.140 · Cited by 115
Elevated LDL Triglycerides and Atherosclerotic Risk
Balling, M., Afzal, S., Smith, G. D., Varbo, A., Langsted, A., Kamstrup, P. R., & Nordestgaard, B. G. (2023) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.10.019 · Cited by 126
Apolipoprotein A-V; a potent triglyceride reducer
Nilsson, S. K., Heeren, J., Olivecrona, G., & Merkel, M. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.07.019 · Cited by 122
Angelakopoulou, A., Shah, T., Sofat, R., Shah, S. H., Berry, D. J., Cooper, J. A., Palmen, J., Tzoulaki, I., Wong, A., Jefferis, B. J. M. H., et al. (2011) · European Heart Journal · doi:10.1093/eurheartj/ehr225 · Cited by 114
Distinctive Biological Correlates of Positive Psychological Well-Being in Older Men and Women
Steptoe, A., Demakakos, P., de Oliveira, C., & Wardle, J. (2012) · Psychosomatic Medicine · doi:10.1097/psy.0b013e31824f82c8 · Cited by 106
Genetics of Triglycerides and the Risk of Atherosclerosis
Dron, J. S., & Hegele, R. A. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0667-9 · Cited by 114
VLDL triglyceride kinetics in lean, overweight, and obese men and women
Mittendorfer, B., Yoshino, M., Patterson, B. W., & Klein, S. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-1500 · Cited by 108
Atherogenic Dyslipidemia and Residual Cardiovascular Risk in Statin-Treated Patients
Sirimarco, G., Labreuche, J., Bruckert, É., Goldstein, L. B., Fox, K. M., Rothwell, P. M., Amarenco, P., Bousser, M., Chamorro, Á., Ford, I., et al. (2014) · Stroke · doi:10.1161/strokeaha.113.004229 · Cited by 108
Triglycerides and risk of atherosclerotic cardiovascular disease: An update
Farnier, M., Zeller, M., Masson, D., & Cottin, Y. (2021) · Archives of cardiovascular diseases · doi:10.1016/j.acvd.2020.11.006 · Cited by 116
Karlson, B. W., Palmer, M. K., Nicholls, S. J., Lundman, P., & Barter, P. J. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.02.011 · Cited by 105
Lindman, A. S., Veierød, M. B., Tverdal, A., Pedersen, J. I., & Selmer, R. M. (2010) · European Journal of Epidemiology · doi:10.1007/s10654-010-9501-1 · Cited by 111
Amerindian-specific regions under positive selection harbour new lipid variants in Latinos
Ko, A., Cantor, R. M., Weissglas‐Volkov, D., Nikkola, E., Reddy, P. M. V. L., Sinsheimer, J. S., Paşaniuc, B., Brown, R., Alvarez, M., Rodríguez, A., et al. (2014) · Nature Communications · doi:10.1038/ncomms4983 · Cited by 108
Orringer, C. E., Jacobson, T. A., & Maki, K. C. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.10.014 · Cited by 103
Piperni, E., Nguyen, L. H., Manghi, P., Kim, H., Pasolli, E., Andreu‐Sánchez, S., Arrè, A., Bermingham, K. M., Blanco‐Míguez, A., Manara, S., et al. (2024) · Cell · doi:10.1016/j.cell.2024.06.018 · Cited by 108
Quispe, R., Martin, S. S., & Jones, S. R. (2016) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000241 · Cited by 97
Lawlor, D. A., Nordestgaard, B. G., Benn, M., Zuccolo, L., Tybjærg‐Hansen, A., & Smith, G. D. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht081 · Cited by 96
Johansen, C. T., Wang, J., Lanktree, M. B., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., Schwartz, S. M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226365 · Cited by 97
Watts, G. F., & Karpe, F. (2011) · Heart · doi:10.1136/hrt.2010.204990 · Cited by 97
Ray, K. K., Corral, P., Morales, E., & Nicholls, S. J. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31950-6 · Cited by 94
Steinarsson, A. O., Rawshani, A., Guðbjörnsdóttir, S., Franzén, S., Svensson, A., & Sattar, N. A. (2018) · Diabetologia · doi:10.1007/s00125-017-4532-8 · Cited by 94
Biomarkers of Calcific Aortic Valve Disease
Small, A., Kiss, D., Giri, J. S., Anwaruddin, S., Siddiqi, H. K., Guerraty, M. A., Chirinos, J. A., Ferrari, G. M., & Rader, D. J. (2017) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.116.308615 · Cited by 98
Hypertriglyceridemia and cardiovascular risk: a cautionary note about metabolic confounding
Sniderman, A. D., Couture, P., Martin, S. S., DEGRAAF, J., Lawler, P. R., Cromwell, W. C., Wilkins, J. T., & Thanassoulis, G. (2018) · Journal of Lipid Research · doi:10.1194/jlr.r082271 · Cited by 91
Management of residual risk after statin therapy
Reith, C. A., & Armitage, J. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.12.018 · Cited by 91
Triglyceride-rich lipoproteins and remnants: targets for therapy?
Dallinga-Thie, G. M., Kroon, J., Borén, J., & Chapman, M. J. (2016) · Current Cardiology Reports · doi:10.1007/s11886-016-0745-6 · Cited by 90
Metabolic syndrome: nature, therapeutic solutions and options
Onat, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.585462 · Cited by 86
Shapiro, A. M., Tümer, N., Gao, Y., Cheng, K., & Scarpace, P. J. (2011) · British Journal Of Nutrition · doi:10.1017/s000711451100033x · Cited by 87
Fasting, non-fasting and postprandial triglycerides for screening cardiometabolic risk
Keirns, B. H., Sciarrillo, C. M., Koemel, N. A., & Emerson, S. R. (2021) · Journal of Nutritional Science · doi:10.1017/jns.2021.73 · Cited by 86
Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease
Martin, A., Lang, S., Goeser, T., Demir, M., Steffen, H., & Kasper, P. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01028-4 · Cited by 93
Triglycerides on the rise: should we swap seats on the seesaw?
Libby, P. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehu500 · Cited by 85
Triglycerides and cardiovascular disease
Esan, O., & Wierzbicki, A. S. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000862 · Cited by 87
Genetics of Coronary Artery Disease
Musunuru, K., & Kathiresan, S. (2010) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-082509-141637 · Cited by 85
Lipoprotein metabolism in nonalcoholic fatty liver disease
Jiang, Z. G., Simon, K. A., & Zemin, Y. (2013) · Journal of Biomedical Research · doi:10.7555/jbr.27.20120077 · Cited by 89
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2012) · Lipids in Health and Disease · doi:10.1186/1476-511x-11-132 · Cited by 84
Kelly, R. K., Tong, T. Y. N., Watling, C. Z., Reynolds, A. N., Piernas, C., Schmidt, J. A., Papier, K., Carter, J. L., Key, T. J., & Perez‐Cornago, A. (2023) · BMC Medicine · doi:10.1186/s12916-022-02712-7 · Cited by 87
Postprandial Hypertriglyceridemia and Cardiovascular Disease: Current and Future Therapies
Chan, D. C., Pang, J., Romic, G., & Watts, G. F. (2013) · Current Atherosclerosis Reports · doi:10.1007/s11883-013-0309-9 · Cited by 79
Guía ESC 2021 sobre la prevención de la enfermedad cardiovascular en la práctica clínica
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Bénétos, A., Biffi, A., Boavida, J. M., Capodanno, D., et al. (2022) · Revista Española de Cardiología · doi:10.1016/j.recesp.2021.10.016 · Cited by 89
Aadland, E. K., Lavigne, C., Graff, I. E., Eng, Ø., Paquette, M., Holthe, A., Mellgren, G., Jacques, H., & Liaset, B. (2015) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.115.112086 · Cited by 77
Genetics of Lipid and Lipoprotein Disorders and Traits
Dron, J. S., & Hegele, R. A. (2016) · Current Genetic Medicine Reports · doi:10.1007/s40142-016-0097-y · Cited by 78
Hermans, M. P., Ahn, S. A., & Rousseau, M. F. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-88 · Cited by 76
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 81
Lamprea-Montealegre, J. A., Staplin, N., Herrington, W. G., Haynes, R., Emberson, J., Baigent, C., de Boer, I. H., & on behalf of the SHARP Collaborative Group (2019) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.07320619 · Cited by 75
Hodson, L., Banerjee, R., Rial, B., Arlt, W., Adiels, M., Borén, J., Marinou, K., Fisher, C., Mostad, I. L., STRATTON, I. M., et al. (2015) · Journal of the American Heart Association · doi:10.1161/jaha.115.002258 · Cited by 73
New Therapeutic Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2016) · Cell Metabolism · doi:10.1016/j.cmet.2016.01.005 · Cited by 75
Almonds and Cardiovascular Health: A Review
Kalita, S., Khandelwal, S., Madan, J., Pandya, H. V., Sesikeran, B., & Krishnaswamy, K. (2018) · Nutrients · doi:10.3390/nu10040468 · Cited by 76
Ryu, N. H., Lim, Y., Park, J. E., Kim, J., Kim, J. Y., Kwon, S. W., & Kwon, O. (2014) · Nutrition Journal · doi:10.1186/1475-2891-13-57 · Cited by 71
Generoso, G., Janovsky, C. C. P. S., & Bittencourt, M. S. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000468 · Cited by 72
Arca, M., Veronesi, C., D’Erasmo, L., Borghi, C., Colivicchi, F., Ferrari, G. M. D., Desideri, G., Pontremoli, R., Temporelli, P. L., Perrone, V., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015801 · Cited by 71
Mendelian randomisation applied to drug development in cardiovascular disease: a review
Mokry, L. E., Ahmad, O. S., Forgetta, V., Thanassoulis, G., & Richards, J. B. (2014) · Journal of Medical Genetics · doi:10.1136/jmedgenet-2014-102438 · Cited by 67
Nordestgaard, B. G., & Tybjærg‐Hansen, A. (2011) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32834477d2 · Cited by 64
Hypertriglyceridemia—causes, significance, and approaches to therapy
Santos-Baez, L. S., & Ginsberg, H. N. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00616 · Cited by 66
Cui, G., Li, Z., Li, R., Huang, J., Wang, H., Zhang, L., Ding, H., & Wang, D. W. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.050 · Cited by 68
Shungin, D., Cornelis, M. C., Divaris, K., Holtfreter, B., Shaffer, J. R., Yu, Y., Barros, S. P., Beck, J. D., Biffar, R., Boerwinkle, E., et al. (2015) · International Journal of Epidemiology · doi:10.1093/ije/dyv075 · Cited by 68
The Role of Emerging Risk Factors in Cardiovascular Outcomes
Lacey, B., Herrington, W. G., Preiss, D., Lewington, S., & Armitage, J. (2017) · Current Atherosclerosis Reports · doi:10.1007/s11883-017-0661-2 · Cited by 69
Guía de la ESC/EAS sobre el manejo de las dislipemias
Reiner, Ž., Catapano, A. L., Backer, G. D., Graham, I. M., Taskinen, M., Wiklund, O., Agewall, S., Alegría, E., Chapman, M. J., Durrington, P. N., et al. (2011) · Revista Española de Cardiología · doi:10.1016/j.recesp.2011.09.014 · Cited by 64
Sosale, A., Saboo, B., & Sosale, B. (2015) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s49592 · Cited by 65
The genetics of coronary heart disease
Swerdlow, D. I., Holmes, M. V., Harrison, S. C., & Humphries, S. E. (2012) · British Medical Bulletin · doi:10.1093/bmb/lds009 · Cited by 64
Maki, K. C., Guyton, J. R., Orringer, C. E., Hamilton-Craig, I., Alexander, D. D., & Davidson, M. H. (2016) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2016.03.008 · Cited by 62
Diet, exercise and weight loss and dyslipidaemia
Clifton, P. M. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.013 · Cited by 66
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Triglycerides and residual risk
Vallejo‐Vaz, A. J., Corral, P., Schreier, L. E., & Ray, K. K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000530 · Cited by 60
Nordestgaard, L. T., Christoffersen, M., Afzal, S., Nordestgaard, B. G., Tybjærg‐Hansen, A., & Frikke‐Schmidt, R. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa269 · Cited by 64
Toth, P. P., Philip, S., HULL, M. L., & Granowitz, C. B. (2019) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2019.03.028 · Cited by 60
Hansen, S. E. J., Madsen, C. M., Varbo, A., Tybjærg‐Hansen, A., & Nordestgaard, B. G. (2020) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2020.08.016 · Cited by 59
Angiopoietin-2 blocking antibodies reduce early atherosclerotic plaque development in mice
Theelen, T. L., Lappalainen, J. P., Sluimer, J. C., Gurzeler, E., Cleutjens, J. P. M., Gijbels, M. J., Biessen, E. A. L., Daemen, M. J. A. P., Alitalo, K. K., & Ylä‐Herttuala, S. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.05.018 · Cited by 58
Mendelian Randomization: Application to Cardiovascular Disease
Timpson, N. J., Wade, K. H., & Smith, G. D. (2011) · Current Hypertension Reports · doi:10.1007/s11906-011-0242-7 · Cited by 60
Xu, C., Bai, R., Zhang, D., Li, Z., Zhu, H., Lai, M., & Zhu, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0056216 · Cited by 57
Galvao, D. A., Taaffe, D. R., Spry, N. A., Joseph, D. J., & Newton, R. U. (2011) · The Journal of Urology · doi:10.1016/j.juro.2011.05.055 · Cited by 57
Hypertriglyceridemia and Cardiovascular Diseases: Revisited
Han, S. H., Nicholls, S. J., Sakuma, I., Zhao, D. H., & Koh, K. K. (2016) · Korean Circulation Journal · doi:10.4070/kcj.2016.46.2.135 · Cited by 60
Hermans, M. P., Ahn, S. A., Mahadeb, Y. P., & Rousseau, M. F. (2013) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2387 · Cited by 56
Allelic and phenotypic spectrum of plasma triglycerides
Johansen, C. T., & Hegele, R. A. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2011.10.007 · Cited by 59
Alssema, M., Rijkelijkhuizen, J. M., Holst, J. J., Teerlink, T., Scheffer, P. G., Eekhoff, E. M. W., Gastaldelli, A., Mari, A., Hart, L. M. ‘., Nijpels, G., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0487 · Cited by 59
Toyama, Y., Chin, K., Chihara, Y., Takegami, M., Takahashi, K., Sumi, K., Nakamura, T., Nakayama-Ashida, Y., Minami, I., Horita, S., et al. (2013) · CHEST Journal · doi:10.1378/chest.12-0338 · Cited by 57
Prenner, S. B., Mulvey, C. K., Ferguson, J. F., Rickels, M. R., Bhatt, A. B., & Reilly, M. P. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.07.008 · Cited by 55
Angelin, B., Kristensen, J. D., Eriksson, M., Carlsson, B., Klein, I. L., OLSSON, A. G., Ridgway, E. C., & Ladenson, P. W. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12261 · Cited by 55
Laclaustra, M., López‐García, E., Civeira, F., García‐Esquinas, E., Graciani, A., Guallar‐Castillón, P., Banegas, J. R., & Rodríguez‐Artalejo, F. (2018) · Diabetes Care · doi:10.2337/dc18-0372 · Cited by 55
Differences in Associations between Visceral Fat Accumulation and Obstructive Sleep Apnea by Sex
Harada, Y., Oga, T., Chihara, Y., Azuma, M., Murase, K., Toyama, Y., Aihara, K., Tanizawa, K., Yoshimura, C., Hitomi, T., et al. (2014) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201306-182oc · Cited by 54
Toth, P. P., Fazio, S., Wong, N. D., HULL, M. L., & Nichols, G. A. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13921 · Cited by 59
Apolipoprotein Proteomics for Residual Lipid-Related Risk in Coronary Heart Disease
Clarke, R., Ende, A. V., Schmidt, L. E., Yin, X., Hill, M., Hughes, A. D., Pechlaner, R., Willeit, J., Kiechl, S. J., Watkins, H. C., et al. (2023) · Circulation Research · doi:10.1161/circresaha.122.321690 · Cited by 52
Isaacs, A. J., Willems, S. M., Bos, D., Dehghan, A., Albert Hofman, D., Ikram, M. A., Uitterlinden, A. G., Oostra, B. A., Franco, O. H., Witteman, J. C. M., et al. (2013) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.113.301236 · Cited by 51
Takeuchi, F., Isono, M., Katsuya, T., Yokota, M., Yamamoto, K., Nabika, T., Shimokawa, K., Nakashima, E., Sugiyama, T., Rakugi, H., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0046385 · Cited by 52
Arca, M., Borghi, C., Pontremoli, R., Ferrari, G. M. D., Colivicchi, F., Desideri, G., & Temporelli, P. L. (2017) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2017.11.001 · Cited by 54
Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice
Lu, Y., Boekschoten, M. V., Wopereis, S., Müller, M. M., & Kersten, S. (2011) · Physiological Genomics · doi:10.1152/physiolgenomics.00100.2011 · Cited by 51
Treatment of lipid disorders in obesity
Tonstad, S., & Després, J. (2011) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.11.83 · Cited by 52
Omega-3 Fatty Acids in Cardiovascular Disease and Diabetes: a Review of Recent Evidence
Bhat, S. Z., Sarkar, S., Zaffar, D., Dandona, P., & Kalyani, R. R. (2023) · Current Cardiology Reports · doi:10.1007/s11886-022-01831-0 · Cited by 51
Ishikawa, T., Ayaori, M., Uto‐Kondo, H., Nakajima, T., Mutoh, M., & Ikewaki, K. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.06.028 · Cited by 52
Inflammatory Links Between Hypertriglyceridemia and Atherogenesis
Peng, X., & Wu, H. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01006-w · Cited by 51
Jackson, S. E., Steptoe, A., Beeken, R. J., Mika Kivimaki, B., & Wardle, J. (2014) · PLoS ONE · doi:10.1371/journal.pone.0104552 · Cited by 49
The role of apolipoprotein A5 in non-alcoholic fatty liver disease
Ress, C., Moschen, A. R., Sausgruber, N., Tschoner, A., Graziadei, I., Weiss, H., Schgoer, W., Ebenbichler, C. F., Konrad, R. J., Patsch, J. R., et al. (2011) · Gut · doi:10.1136/gut.2010.222224 · Cited by 49
Trautwein, E. A., Koppenol, W. P., de Jong, A., Hiemstra, H., Vermeer, M. A., Noakes, M., & Luscombe‐Marsh, N. D. (2018) · Nutrition and Diabetes · doi:10.1038/s41387-018-0039-8 · Cited by 51
Jain, N., Bhansali, S., Kurpad, A. V., Hawkins, M. A., Sharma, A. D., Kaur, S., Rastogi, A., & Bhansali, A. K. (2019) · Scientific Reports · doi:10.1038/s41598-019-55466-3 · Cited by 49
Strong association of the APOA5-1131T>C gene variant and early-onset acute myocardial infarction
Caterina, R. D., Talmud, P. J., Merlini, P. A., Foco, L., Pastorino, R., Altshuler, D., Mauri, F., Peyvandi, F., Lina, D., Kathiresan, S., et al. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.11.011 · Cited by 47
Richardson, T. G., Mykkänen, J., Pahkala, K., Ala‐Korpela, M., Bell, J. A., Taylor, K., Viikari, J. S. A., Lehtimäki, T. J., Raitakari, O. T., & Smith, G. D. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab051 · Cited by 50
Shu, X., Nelbach, L., Weinstein, M. M., Burgess, B. L., Beckstead, J. A., Young, S. G., Ryan, R. O., & Forte, T. M. (2010) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.110.210815 · Cited by 47
de Castro-Orós, I., Cenarro, A., Tejedor, M. T., Baila-Rueda, L., Mateo‐Gállego, R., Lamíquiz-Moneo, I., Pocovı́, M., & Civeira, F. (2014) · Circulation Cardiovascular Genetics · doi:10.1161/circgenetics.114.000522 · Cited by 49
Metadata
- Authors
- ‡
- Affiliations
- University of Cambridge (GB)
- Corresponding author
- ‡
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2010-05
- Volume
- 375
- Issue
- 9726
- Pages
- 1634-1639
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- PMC
- PMC2867029
- OpenAlex
- W2144516660
- Cited by
- 716
- References
- 37
- Citations by year
- 2026: 10 · 2025: 24 · 2024: 29 · 2023: 29 · 2022: 47 · 2021: 49 · 2020: 53 · 2019: 55 · 2018: 50 · 2017: 36 · 2016: 51 · 2015: 51 · 2014: 48 · 2013: 45 · 2012: 47
- FWCI
- 62.17
- Type
- journal article
- Language
- en
- Update notices
- erratum (2010-07-10)
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Pure Amsterdam UMC (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, other-oa)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Bristol Research (University of Bristol) (publishedVersion)
- Socio-Environmental Systems Modeling (acceptedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Leiden Repository (Leiden University) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Figshare (submittedVersion)
- Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
- Explore Bristol Research (submittedVersion)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Funders
- British Heart Foundation
- Novartis
- Medical Research Council
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- triglycerides, coronary artery disease, APOA5, APOA5 -1131T>C polymorphism, genetic association, triglyceride concentration, HDL cholesterol, apolipoprotein A-I, apolipoprotein B, lipoprotein concentration, lipoprotein particle size, causal inference, genetic risk factors
- MeSH terms
- Apolipoprotein A-V, Apolipoproteins, Apolipoproteins A, Coronary Disease, Gene Frequency, Genotype, Humans, Lipids, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Particle Size, Promoter Regions, Genetic, Risk Factors, Triglycerides, Polymorphism, Single Nucleotide, Mendelian Randomization Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
